{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:10:53Z","timestamp":1791472253439,"version":"4.3.4"},"reference-count":58,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:sec id=\"ab-ioi240077-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Clinicians often approach urate-lowering therapy (ULT) cautiously in patients with gout and impaired kidney function because they are concerned about the risk of progression to severe or end-stage kidney disease. However, evidence from randomized clinical trials of this association remains inconclusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi240077-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between achieving target serum urate level with ULT and progression of chronic kidney disease (CKD) to severe or end-stage in patients with gout and impaired kidney function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi240077-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a cohort study using the target trial emulation approach using data from a general practice database (IQVIA Medical Research Database) for 2000 to 2023. Eligible patients were 40 to 89 years old and had gout and CKD stage 3. Data analyses were performed from November 2023 to September 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi240077-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Lowering serum urate level to target level (&amp;amp;lt;6 mg\/dL) using ULT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi240077-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>\n                      Severe or end-stage kidney disease, determined by an estimated glomerular filtration rate of less than 30 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      on at least 2 occasions more than 90 days apart within 1 year, or at least 1 Read code (per the Refined Etiology, Anatomical Site, and Diagnosis classification) for CKD stages 4 or 5, hemodialysis, peritoneal dialysis, or kidney transplant. The prespecified noninferiority margin of the hazard ratio (HR) was set at 1.2, comparing those who achieved the target serum urate level with those who did not.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi240077-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 14\u202f792 participants (mean [SD] age, 73.1 [9.5] years; 9215 men [62.3%] and 5577 women [37.7%]) with gout and with CKD stage 3, the 5-year risk of severe or end-stage kidney disease was 10.32% for those who achieved the target serum urate level and 12.73% for those who did not. Compared with those not achieving the target level, the adjusted 5-year risk difference and HR of severe or end-stage kidney disease for patients achieving the target serum urate level was \u22122.41% (95% CI, \u22124.61% to \u22120.21%) and 0.89 (95% CI, 0.80 to 0.98), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi240077-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The findings of this cohort study indicate that in patients with gout and CKD stage 3, lowering serum urate level to less than 6 mg\/dL vs 6 mg\/dL or greater using ULT was not associated with an increased risk of severe or end-stage kidney disease. These findings support optimizing ULT to achieve target serum urate levels when treating patients with gout and impaired kidney function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2024.6212","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T11:32:56Z","timestamp":1732534376000},"page":"74","source":"Crossref","is-referenced-by-count":39,"title":["Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease"],"prefix":"10.1001","volume":"185","author":[{"given":"Yilun","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Terkeltaub","sequence":"additional","affiliation":[{"name":"University of California at San Diego, La Jolla, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Li","sequence":"additional","affiliation":[{"name":"Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Key Laboratory of Aging-Related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghua","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Key Laboratory of Aging-Related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Key Laboratory of Aging-Related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"},{"name":"Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3S","key":"ioi240077r1","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","article-title":"Gout epidemiology and comorbidities.","volume":"50","author":"Singh","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"ioi240077r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.9501","article-title":"Trends in prevalence of gout among US Asian adults, 2011-2018.","volume":"6","author":"Yokose","year":"2023","journal-title":"JAMA Netw Open"},{"key":"ioi240077r3","doi-asserted-by":"publisher","DOI":"10.2196\/45943","article-title":"Global, regional, and national prevalence of gout from 1990 to 2019: age-period-cohort analysis with future burden prediction.","volume":"9","author":"He","year":"2023","journal-title":"JMIR Public Health Surveill"},{"issue":"7","key":"ioi240077r4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout.","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"issue":"5","key":"ioi240077r5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","article-title":"Association between gout flare and subsequent cardiovascular events among patients with gout.","volume":"328","author":"Cipolletta","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"ioi240077r6","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/art.42480","article-title":"Risk of venous thromboembolism with gout flares.","volume":"75","author":"Cipolletta","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"10156","key":"ioi240077r7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"ioi240077r8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/2040622315618393","article-title":"Gout: optimizing treatment to achieve a disease cure.","volume":"7","author":"Bernal","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"issue":"12","key":"ioi240077r9","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/art.40233","article-title":"Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study.","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"ioi240077r10","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100028","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management.","volume":"1","author":"O\u2019Dell","year":"2022","journal-title":"NEJM Evid"},{"issue":"10156","key":"ioi240077r11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"ioi240077r12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout.","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"ioi240077r13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout.","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"ioi240077r14","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1001\/jama.2014.14484","article-title":"Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England.","volume":"312","author":"Kuo","year":"2014","journal-title":"JAMA"},{"issue":"16","key":"ioi240077r15","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40265-023-01944-y","article-title":"Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review.","volume":"83","author":"Terkeltaub","year":"2023","journal-title":"Drugs"},{"issue":"4","key":"ioi240077r16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.semarthrit.2021.04.011","article-title":"Global patterns of treat-to-serum urate target care for gout: systematic review and meta-analysis.","volume":"51","author":"Son","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ioi240077r17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2147\/PPA.S97927","article-title":"Treatment approaches and adherence to urate-lowering therapy for patients with gout.","volume":"11","author":"Aung","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"ioi240077r18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008.","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"issue":"3","key":"ioi240077r19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1681\/ASN.2004030208","article-title":"Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study.","volume":"16","author":"Domrongkitchaiporn","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"ioi240077r20","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1681\/ASN.2007101075","article-title":"Uric acid and incident kidney disease in the community.","volume":"19","author":"Weiner","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"ioi240077r21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3109\/03009742.2010.507218","article-title":"Hyperuricaemia and accelerated reduction in renal function.","volume":"40","author":"Kuo","year":"2011","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"ioi240077r22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4103\/0971-4065.114499","article-title":"Allopurinol for prevention of progression of kidney disease with hyperuricemia.","volume":"23","author":"Pai","year":"2013","journal-title":"Indian J Nephrol"},{"issue":"9","key":"ioi240077r23","first-page":"1620","article-title":"Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.","volume":"33","author":"Chou","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"ioi240077r24","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.3899\/jrheum.150067","article-title":"Effect of urate lowering therapy on renal disease progression in hyperuricemic patients with chronic kidney disease.","volume":"42","author":"Kim","year":"2015","journal-title":"J Rheumatol"},{"issue":"4","key":"ioi240077r25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","article-title":"Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.","volume":"65","author":"Goicoechea","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"ioi240077r26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial.","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"ioi240077r27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"26","key":"ioi240077r28","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease.","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"ioi240077r29","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes.","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"ioi240077r30","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1681\/ASN.0000000000000326","article-title":"Combination treatment with verinurad and allopurinol in CKD: a randomized placebo and active controlled trial.","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"ioi240077r31","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/art.39654","article-title":"Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment.","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"ioi240077r32","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.amjmed.2015.05.033","article-title":"Reducing prescribing errors through creatinine clearance alert redesign.","volume":"128","author":"Melton","year":"2015","journal-title":"Am J Med"},{"issue":"4","key":"ioi240077r33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.kint.2024.05.033","article-title":"Controversies and practical management of patients with gout and chronic kidney disease.","volume":"106","author":"Johnson","year":"2024","journal-title":"Kidney Int"},{"issue":"11","key":"ioi240077r34","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1001\/jamainternmed.2018.4463","article-title":"Association of chronic kidney disease with allopurinol use in gout treatment.","volume":"178","author":"Vargas-Santos","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"3","key":"ioi240077r35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1046\/j.1365-2532.1994.1130177.x","article-title":"What are the Read codes?","volume":"11","author":"Booth","year":"1994","journal-title":"Health Libr Rev"},{"issue":"4","key":"ioi240077r36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/pds.1335","article-title":"Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.","volume":"16","author":"Lewis","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"ioi240077r37","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.2019.1347","article-title":"Association of tramadol with all-cause mortality among patients with osteoarthritis.","volume":"321","author":"Zeng","year":"2019","journal-title":"JAMA"},{"issue":"12","key":"ioi240077r38","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/art.39330","article-title":"Sleep apnea and the risk of incident gout: a population-based, body mass index-matched cohort study.","volume":"67","author":"Zhang","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"ioi240077r39","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3899\/jrheum.170444","article-title":"Gout and the risk of incident erectile dysfunction: a body mass index-matched population-based study.","volume":"45","author":"Schlesinger","year":"2018","journal-title":"J Rheumatol"},{"issue":"4","key":"ioi240077r40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M21-2347","article-title":"Allopurinol initiation and all-cause mortality among patients with gout and concurrent chronic kidney disease: a population-based cohort study.","volume":"175","author":"Wei","year":"2022","journal-title":"Ann Intern Med"},{"issue":"7","key":"ioi240077r41","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7326\/M20-0882","article-title":"Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study.","volume":"173","author":"Lyu","year":"2020","journal-title":"Ann Intern Med"},{"issue":"8","key":"ioi240077r42","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"ioi240077r43","doi-asserted-by":"publisher","first-page":"k182","DOI":"10.1136\/bmj.k182","article-title":"How to estimate the effect of treatment duration on survival outcomes using observational data.","volume":"360","author":"Hern\u00e1n","year":"2018","journal-title":"BMJ"},{"issue":"6","key":"ioi240077r44","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"1","key":"ioi240077r45","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12874-016-0248-6","article-title":"A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study.","volume":"16","author":"Ngwa","year":"2016","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"ioi240077r47","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial.","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"ioi240077r48","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1159\/000087713","article-title":"Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter.","volume":"25","author":"Kang","year":"2005","journal-title":"Am J Nephrol"},{"issue":"2","key":"ioi240077r49","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1097-2765(00)80139-2","article-title":"Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice.","volume":"2","author":"Gu","year":"1998","journal-title":"Mol Cell"},{"issue":"6","key":"ioi240077r50","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1161\/01.HYP.0000072820.07472.3B","article-title":"Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2.","volume":"41","author":"Kanellis","year":"2003","journal-title":"Hypertension"},{"issue":"12","key":"ioi240077r51","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1681\/ASN.2020040523","article-title":"Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease.","volume":"31","author":"Sellmayr","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"ioi240077r52","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/ki.2011.198","article-title":"Biomarkers in chronic kidney disease: a review.","volume":"80","author":"Fassett","year":"2011","journal-title":"Kidney Int"},{"issue":"Pt 3","key":"ioi240077r53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1113\/jphysiol.2003.055913","article-title":"Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.","volume":"555","author":"Berry","year":"2004","journal-title":"J Physiol"},{"issue":"5","key":"ioi240077r54","doi-asserted-by":"publisher","first-page":"F765","DOI":"10.1152\/ajprenal.00236.2020","article-title":"Non-purine selective xanthine oxidase inhibitor ameliorates glomerular endothelial injury in InsAkita diabetic mice.","volume":"319","author":"Itano","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"ioi240077r55","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/art.33369","article-title":"Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal.","volume":"64","author":"Neogi","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"ioi240077r56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050046","article-title":"Reduced glomerular function and prevalence of gout: NHANES 2009-10.","volume":"7","author":"Krishnan","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"ioi240077r57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"ioi240077r58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0300-2977(97)00088-0","article-title":"The allopurinol hypersensitivity syndrome.","volume":"52","author":"Pluim","year":"1998","journal-title":"Neth J Med"},{"key":"ioi240077r46","volume-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"2004"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2826331\/jamainternal_wang_2024_oi_240077_1735588710.93619.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T11:03:02Z","timestamp":1736161382000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2826331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2024.6212","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}